image4

Charles A. Sanders, M.D.

Chairman

introimage

Maria C.
Freire, Ph.D.

President

Letter from the Chairman and President

Open post

The power of our
organizational structure.
The Foundation for the National Institutes of Health (FNIH) was founded in 1996 by an act of Congress as a 501(c)(3) not-for-profit that can raise private funds in support of the NIH mission. In addition to raising funds—more than $830 million since our founding—the FNIH has excelled at creating innovative cross-sector partnerships in a neutral, pre-competitive environment to tackle large biomedical challenges with great urgency and efficiency. These partnerships offer a new way of generating the discoveries that improve health and change people’s lives for the better. For 10 years, Charity Navigator has rated FNIH as an organization that exceeds industry standards and performs as well or better than most charities.

There is an old adage that it takes years to become an overnight sensation. Indeed, in many fields, decades of planning, study and hard work eventually make possible what seems a sudden success story. For example, the phrase “public-private partnerships” is ubiquitous in some circles, but for many, a new concept. For the Foundation for the National Institutes of Health (FNIH), however, it is a successful way to drive progress—a formula we have used for nearly 20 years to build innovative and strategic alliances between the public and private sectors. These partnerships are crucial to the advancement of biomedical science because they provide a vehicle to create and support trailblazing projects and programs that enhance the mission of the National Institutes of Health (NIH).

Another of today’s most popular terms—born from decades of scientific and clinical research—is “precision medicine”: tailoring treatment to the needs and make-up of an individual. The potential impact on health due to such technologically advanced medicine is enormous and demonstrates why funding for medical research must be, and must remain, a national priority. This new way of preventing, diagnosing and treating disease did not happen overnight; it took strong investment from the U.S. government for basic research, unwavering dedication from scientists in academia, the private and the public sectors, generous philanthropic support from donors and, importantly, the unselfish commitment of thousands of patients who volunteer to become partners in the medical research enterprise.

The FNIH is uniquely positioned to work with these stakeholders to create partnerships that have transformed business-as-usual into business success. In this report, we are pleased to highlight some of the pioneering programs of the robust FNIH portfolio, including a new model for clinical trials that speed patient access to investigational drugs (Lung-MAP), new interventions that enhance the lives and health of some of the world’s poorest people (HIT-TB) and a radically new approach to early-stage drug development (AMP).

Yet there are challenges. In recent years, the NIH budget has suffered losses, both in real and inflation-adjusted dollars. A government shutdown and sequestration compounded the situation. If as a society we are to continue progress towards revolutionizing our ability to tackle disease and disability, this trend must be reversed to regain momentum.

The staff of the FNIH is inspired by our mission to help the NIH turn discovery into improved health. With the generous support of the biomedical community, our funders and our partners, we continue to leverage public and private funds to advance biomedical science forward through innovative leading-edge initiatives.

FNIH
at-a-Glance

  • Creating and managing a diverse portfolio or initiatives.
  • Developing diverse and uncommon collaborations.
Open post

OUR PARTNERSHIPS

Everything we do depends on collaboration. The partnerships we forge provide funding support as well as expertise and resources to help us accomplish and expand our work. What we achieve collectively is far greater than that of any single organization.

fnih-graph

WHAT WE DO

The FNIH stands at the center of a broad portfolio of initiatives focused on shared goals: advancing biomedical science to improve lives and supporting the mission of the NIH. One of the most important jobs the FNIH does is fundraising—without the ongoing support of our contributors these initiatives would not be possible.

RESEARCH PARTNERSHIPS — We develop collaborations with top experts from government, industry, academia and the not-for-profit sector and provide a neutral environment where we can work productively toward a common goal. Examples include:

  • Portfolio Supporting NIH Research — Supporting and raising funds for multiple projects initiated by the NIH, while also convening the right partners within and outside of the NIH.
  • Global Health — Coordinating and operating more than 50 collaborative projects in over 33 countries, including the Grand Challenges in Global Health (GCGH) supported by the Bill & Melinda Gates Foundation.
  • Biomarkers Consortium — Initiating and managing more than 16 projects funded with over $50 million in private dollars, designed to discover and develop biological markers to support new drug development, preventive medicine and medical diagnostics.

SYMPOSIA, EVENTS & EXHIBITS — We organize and facilitate more than 60 events each year, creating a forum for innovative thinkers in biomedical sciences to share ideas and engage the public in disease and health awareness.

FELLOWSHIPS & AWARDS — We provide funding for training for early-career scientists, along with support and recognition for researchers whose findings have advanced biomedical science.

SUPPORT FOR THE NIH RESEARCH ENTERPRISE   — Each year, FNIH undertakes a variety of projects to support the NIH community of researchers, patients and stakeholders. For example, in 2014, the FNIH raised funds to support renovations and enhancements to the The Edmond J. Safra Family Lodge, a facility that provides temporary housing for families of patients receiving care at the NIH Clinical Center.

2014
Highlights

  • Cultivating Collaborations that Thrive.
  • Creating Impact Beyond the Laboratory.
  • Bringing Bold Thinking to New Models.
Open post

A NEW VISION FOR DISCOVERY. Today’s health challenges are too complex to be solved by any single organization—government, business, academia or not-for-profit—working in isolation. But often these organizations are not experienced at identifying partners and forging productive relationships. At the FNIH, we are connected to key players in all of these sectors, and we can facilitate their collaboration because we have created management and funding models that make large-scale, multi-partner projects succeed. This is our vision for discovery—and it works.

Cultivating Collaborations that Thrive

img01

Joining forces to accelerate drug development

New medicines that show promise in the laboratory often do not succeed in human testing. In fact, about 95 percent fail, typically late in the clinical trials process after millions of dollars have been invested. Such a high-cost, low-reward pipeline points to the need for a better understanding of how diseases develop at the molecular level—which is why the FNIH is helping to lead an unprecedented partnership to fill this need. Launched in 2014, the Accelerating Medicines Partnership (AMP) is a $230 million, five-year effort joining the forces of the FNIH, the NIH and the Food and Drug Administration (FDA) with those of not-for-profit organizations and 10 biopharmaceutical companies to devise a radically new approach to early-stage drug development. These companies have agreed to share expertise, resources and data to answer a critical question: Which biological pathways underlying a given disease are the best candidates for targeting new treatments? Instead of having different organizations pursue disparate pathways in isolation, AMP will generate pre-competitive, disease-specific data on the genetic and biological markers most likely to yield success when used as targets for new medicines. The data will be publicly available to the biomedical community so that many can use it as the foundation for drug discovery.

[List of AMP Partners]

[ close ]

Accelerating Medicines Partnership (AMP)

Private Industry:

AbbVie

Biogen

Bristol-Myers Squibb Company

Eli Lilly and Company

GlaxoSmithKline

Janssen Research & Development, LLC

Merck Sharp & Dohme Corp.

Pfizer Inc

Sanofi

Takeda Pharmaceuticals

Not-for-Profit:

Alliance for Lupus Research

Alzheimer’s Association®

Alzheimer’s Drug Discovery Foundation

American Diabetes Association

Arthritis Foundation

Geoffrey Beene Foundation
Alzheimer’s Initiative

JDRF International

The Lupus Foundation of America

Lupus Research Institute

Pharmaceutical Research and Manufacturers of America

Rheumatology Research Foundation

USAgainstAlzheimer’s

AMP: Type 2 Diabetes

More than 100 million Americans already have type 2 diabetes or are at high risk, and 382 million people worldwide have a type 2 diagnosis. Although therapies are available, none can reverse the disease process or prevent the progression that leads to life-altering complications such as cardiovascular and kidney disease, limb loss and blindness. AMP partners will leverage the substantial amount of data already available from patients with type 2 diabetes and those at high risk to identify and validate DNA regions critical in the development or progression of the disease, with an eye toward identifying potential drug targets.

AMP: Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common form of dementia, a condition that affects 36 million people globally—a number expected to skyrocket to 115 million by 2050 unless an effective therapy is developed. Scientists know that people with AD have the signature protein-based brain lesions called plaques and tangles; however, efforts to harness this knowledge to develop new therapies have not succeeded. AMP partners are working to establish an expanded set of biological markers that are present when AD develops, and then determine which are most promising for developing new treatments and predicting the likelihood of clinical response. The project will involve the large-scale analysis of brain tissue from AD patients and clinical trials to validate newly identified biomarkers.

image3

AMP: Rheumatoid Arthritis & Lupus

Rheumatoid arthritis (RA) and lupus are just two of many disorders that occur when the immune system mistakenly attacks parts of the body that it is designed to protect, leading to inflammation that destroys tissues. Anti-inflammatory treatments can help, but most people with RA respond to current treatments only partially or temporarily. In the case of lupus, no effective targeted therapies exist for the most severe forms of the disease. AMP partners will analyze tissue and blood samples from people with RA and lupus to pinpoint genes, proteins, chemical pathways and networks involved at the cellular level. This is essential for developing targeted treatments for these debilitating conditions, but it also could shed light on the autoimmune process implicated in a wide range of diseases.

Creating Impact Beyond the Laboratory

a

The search for better tuberculosis treatments

Tuberculosis (TB) affected nine million people and caused 1.5 million deaths worldwide in 2013, affecting children and adults with HIV in developing nations particularly hard. TB is a bacterial infection that spreads through the air and attacks the respiratory system and other organs. Successful treatment requires taking multiple medications for several months, leading many patients to drop out prematurely—and remain contagious. Compounding this problem is the growing number of cases that are resistant to available drugs, most developed in the 1970s. With funding through the Bill & Melinda Gates Foundation, the Identification of high-quality HITs for Tuberculosis (HIT-TB) project at the FINH is helping to accelerate the search for new TB medications that could shorten and simplify treatment. This partnership includes the National Institute of Allergy and Infectious Diseases (NIAID), multiple pharmaceutical and agrichemical companies and several academic institutions to speed identification of compounds best suited for testing as potential drugs. The partners have shared their compound libraries and are using high-throughput screening to evaluate many molecules at once to identify “hits” to be prioritized for further study.

b

Genome exhibit reaches millions

Between June 2013 and August 2014, roughly three million Smithsonian visitors experienced Genome: Unlocking Life’s Code at the National Museum of Natural History, an exhibition made possible through funds raised, in part, by the FNIH. The result of a collaboration between the museum and the National Human Genome Research Institute, Genome awed visitors with the complexity and power of the human genome using 3-D models, interactive displays, custom animations and videos of real-life stories. It celebrated the 10th anniversary of the Human Genome Project and the successful sequencing of the human genetic blueprint, helping viewers understand how this knowledge is revolutionizing our understanding of human development, diversity and society, especially health and disease. In addition to the 4,400-square-foot exhibition itself, which took two years for museum designers and educators to develop and build, Genome included public events, educational symposia, an educators’ guide and the website www.unlockinglifescode.org. Genome is now on a multi-city tour that will take it to museums in California, the Midwest and Ontario through early 2018.
For an exhibition schedule, visit http://unlockinglifescode.org/traveling-exhibit

c

Support for a game-changing scientist

What if we could remove and replace damaged or defective parts of human DNA? Scientists have been working to find such a genome-editing tool, but Jennifer Doudna, Ph.D., Professor of Biochemistry, Biophysics and Structural Biology and a Howard Hughes Medical Institute Investigator at the University of California, Berkeley, stands apart. Dr. Doudna has focused her research on the structure of RNA, the molecule that carries out DNA instructions for creating the proteins that drive processes in the body. The FNIH awarded her the Lurie Prize in Biomedical Sciences in 2014 for that body of study, which includes her work on CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), that are repetitive RNA sequences in bacteria that play a role in their immunity. Doudna discovered that pieces of CRISPR RNA team up with a protein called Cas9 to cut through the DNA of an invading virus. Doudna and her team then engineered their own RNA/protein combination and showed it can be used to precisely edit the DNA of plants, animals and humans. This CRISPR tool has to be managed with careful attention to bioethical concerns, but it could function as “molecular scissors” that can fix faulty genes underlying a range of diseases and health conditions.

Bringing Bold Thinking to New Models

d

Lung cancer: pioneering a more efficient approach to clinical trials

Patients with advanced squamous cell lung cancer have few good treatment options beyond surgery, yet the pace of traditional clinical trials remains slow, with most potential treatments never making it to the bedside. The Lung Cancer Master Protocol (Lung-MAP) trial, the result of a partnership that includes the FNIH, is pioneering a new model designed to speed access to investigational drugs for patients and allow multiple researchers to share one umbrella structure and recruitment process, significantly increasing their efficiency. Launched in June 2014, Lung-MAP uses genomic profiling technology to test patients for over 200 cancer-related genetic alterations, then assigns them to one of a number of investigational treatment studies based on their genetic profile. Within its first six months, Lung-MAP was enrolling patients at more than 400 sites in 39 states. The trial will add new investigational treatments over time, with the ultimate goal of testing 10 to 12 targeted therapies in 5,000 patients over the next five years. Besides the FNIH, partners in the effort include the National Cancer Institute, SWOG Cancer Research, Friends of Cancer Research, Foundation Medicine, five pharmaceutical companies and several lung cancer advocacy groups.

[Lung-MAP Partners]

[ close ]

LUNG-MAP PARTNERS

American Lung Association

Amgen, Inc.

AstraZeneca Pharmaceuticals, LP

Genentech

MedImmune

Pfizer Inc

Lung-MAP Design Phase:

Amgen, Inc

AstraZeneca

Boehringer Ingelheim

Genentech

Janssen Research & Development, LLC

Eli Lilly and Company

Novartis Pharmaceuticals Corporation

Andrew & Lillian A. Posey Foundation

LUNGevity Foundation

e

Sarcopenia: defining diagnostic criteria for age-related muscle loss

Sarcopenia—age-related muscle loss and weakness—affects nearly 1 in 3 people over 60 and half of those over age 80. However, lack of an evidence-based definition for sarcopenia has limited our ability to understand its progression and develop strategies for prevention and treatment. This changed in April 2014 with the landmark publication of six special online articles in the Journals of Gerontology: Medical Sciences, which set forth data-driven diagnostic criteria for sarcopenia, including definitions of grip strength and muscle mass. The articles resulted from a collaborative project by the FNIH Biomarkers Consortium, the FDA, the National Institute on Aging and several pharmaceutical companies, in which researchers analyzed data from nine long-term epidemiologic studies involving over 26,000 healthy participants to generate a definition of sarcopenia. In addition to diagnostic criteria, the 2014 publications provide specific characterizations of how low lean mass and low strength relate to problems with mobility. This new information is expected to influence treatment decisions and help identify groups of at-risk patients who are good candidates for testing interventions.

[Biomarkers Consortium—Sarcopenia Partners]

[ close ]

BIOMARKERS CONSORTIUM—
SARCOPENIA PARTNERS

Abbott Nutrition

Amgen, Inc.

Dairy Research Institute

Eli Lilly and Company

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

f

River blindness: moving beyond control to elimination

Over the past few decades, focused efforts to control the tropical disease onchocerciasis, or river blindness, have drastically lowered incidence in South and Central America, but the disease continues to have a devastating impact in sub-Saharan Africa. River blindness is caused by Onchocerca volvulus worms, which are transmitted to humans through repeated bites from infected blackflies. Mass administration of the drug ivermectin is an effective control strategy, but it does not guarantee elimination of the disease from a population, as people can carry the worms without exhibiting symptoms. The FNIH is working with the NIAID to determine if a blood or urine test could be developed to identify people who are carriers of adult female Onchocerca volvulus worms (OvAF). Once inside a human host, these females produce smaller larvae that over time can cause chronic skin disease, severe itching and eye lesions that lead to blindness. Knowing if someone is a carrier would ensure they could be treated and prevent transmission of the worms to uninfected blackflies. The FNIH and NIAID are studying OvAF and OvAF-infected humans to identify biomarkers in blood and urine that might indicate the presence of the female worm, and then test and validate the most promising candidates. The ultimate goal is a point-of-care test that would help eradicate river blindness around the globe.

Financial Highlights

Open post

2014 Revenues

    2014 Revenues

      TOTAL REVENUE AND SUPPORT $76,561,089  $60,373,946
      REVENUE AND SUPPORT 2014 2013
      Contributions  $72,770,911 $57,747,975
      Grants 634,635  887,026
      Administrative fee 197,177 333,361
      Government appropriations 500,000  500,000
      Investment earnings 206,479 337,389
      In-kind contributions 1,724,619  589,208
      Donated services 188,637 43,000
      Fundraising event 184,675 —
      Other revenue 153,956  150,775
      Reduction of future pledges  —  (214,788)

      EXPENSES AND CHANGES IN NET ASSETS

      TOTAL PROGRAM SERVICES

      $71,931,053

      $58,009,886
      PROGRAM SERVICES
      Fellowships and training programs $1,605,067 $1,381,328
      Memorials, awards and events  442,058  1,299,278
      Capital projects 103,421 38,754
      Research partnerships 69,780,507 55,290,526

      TOTAL SUPPORTING SERVICES

      $4,199,073

      $3,456,183
      SUPPORTING SERVICES
      Management and general $3,928,920 $3,352,175
      Fundraising 270,153 104,008
      TOTAL EXPENSES  $76,130,126  $61,466,069
      CHANGE IN NET ASSETS $430,963 $(1,092,123)
      NET ASSETS BEGINNING OF YEAR 91,138,418 92,230,541
      NET ASSETS AT END OF YEAR  $91,569,381 $91,138,418 
      The Foundation's audited financial statements are available on request.

      Contributors

      Open post
      Our Donors

      All FNIH donors play a critical role in providing the resources that are vital to our success. Unrestricted gifts allow us the flexibility to place them where they are most needed, from supporting core operations to developing new partnerships and emerging program ideas. Donors also can choose to restrict their gifts to one area of interest, such as a biomedical research program; a fellowship, lecture or symposium that trains scientists and helps them build their careers; or a specific laboratory or area of scientific research at the NIH.

      We are grateful to the many individuals and organizations who made donations, gifts and pledges in 2014. Every attempt is made to list donors according to their wishes. For a more complete list of donors, funds and endowments, visit fnih.org/about/foundation/annual-reports. Please call 301.402.4976 if you have any questions.

      Of every dollar spent, 94 cents are used to support programs and just six cents for administration and fundraising.

      charity-nav

      For 10 years, Charity Navigator has rated FNIH as an organization that exceeds industry standards and performs as well or better than most charities.

      $250,000–$5,000,000+

      $5,000,000+

      AbbVie Inc.

      Amgen, Inc.12

      AstraZeneca Pharmaceuticals, LP13

      Bill & Melinda Gates Foundation13

      Biogen4

      Eli Lilly and Company8

      Genentech, Inc.8

      GlaxoSmithKline16

      Johnson & Johnson14

      Merck Sharp & Dohme Corp.17

      National Football League

      Pfizer Inc17

      Sanofi*13

      [x] Superscript indicates number of years of consecutive giving.
      * Indicates Gifts in Kind.

      $2,500,000–$4,999,999

      Bristol-Myers Squibb Company15

      Takeda Pharmaceuticals International, Inc.6

      $1,000,000 – $2,499,999

      Doris Duke Charitable Foundation

      McKnight Brain Research Foundation9

      Novartis Pharmaceuticals Corporation*15

      QuantumLeap Healthcare Collaborative

      Regeneron Pharmaceuticals, Inc.2

      $500,000 – $999,999

      Alzheimer’s Association10

      Daiichi Sankyo, Inc.5

      National Institutes of Health19

      $250,000 – $499,999

      Abbott7

      Astellas Pharma Inc.

      Boehringer Ingelheim Pharmaceuticals, Inc.*6

      JSI Research & Training Institute, Inc.

      Juvenile Diabetes Research Foundation International

      The Pew Charitable Trusts

      Pharmaceutical Research and Manufacturers
      of America10

      Mrs. Lily Safra13

      United States Agency for International Development

      [_/su_spoiler]
      $50,000–$249,999

      $100,000 – $249,999

      Alzheimer’s Drug Discovery Foundation2

      Arthritis Foundation5

      The Geoffrey Beene Foundation2

      Bioiberica S.A.

      Eisai Inc. 8

      Healthcare Information and
      Management Systems Society4

      Howard Hughes Medical Institute3

      Ikaria, Inc.2

      [x] Superscript indicates number of years of consecutive giving.
      * Indicates Gifts in Kind.

      Ann Lurie3

      Lundbeck

      Piramal Imaging, GmbH4

      ROCHE7

      Richard and Susan Roth

      $50,000 – $99,999

      Actelion Pharmaceuticals Ltd.4

      Alliance for Lupus Research

      American Association for Dental Research2

      Bayer HealthCare Pharmaceuticals Inc.2

      The Coca-Cola Company7

      Cubist Pharmaceuticals, Inc.

      James H. and Christina W. Donovan3

      John J. Donovan

      Fujirebio3

      Intel Corporation*

      Lupus Research Institute

      The Medicines Company

      Merck Serono2

      PhRMA Foundation7

      Rheumatology Research Foundation

      George and Trish Vradenburg,
      Co-Founders USAgainst Alzheimer’s3

      [_/su_spoiler]
      $5,000–$49,999

      $25,000 – $49,999

      Alliance for Aging Research3

      American Diabetes Association5

      American Lung Association

      AMS Foundation for the Arts,
      Sciences and Humanities10

      BioClinica, Inc.5

      Biotechnology Industry Organization7

      Blue Cross and Blue Shield Association

      Buffy Cafritz11

      Colgate-Palmolive Company2

      John and Marcia Goldman Foundation

      Grifols Therapeutics3

      Hogan Lovells US LLP*5

      IXICO Ltd.3

      Peter and Judy Kovler
      in honor of Maria Freire

      Freda C. Lewis-Hall, M.D., FAPA2

      The Lupus Foundation of America

      Mr. and Mrs. Joel S. Marcus4

      Meso Scale Diagnostics, LLC.6

      Mr. and Mrs. Paul M. Montrone17

      Nabriva Therapeutics AG4

      NeuroRx3

      Newport Foundation, Inc.2

      Dame Jillian Sackler12

      SYNARC Inc.7

      [x] Superscript indicates number of years of consecutive giving.
      * Indicates Gifts in Kind.

      $10,000–$24,999

      Janet B. Abrams6
      in memory of Bernard Abrams

      Agilent Technologies, Inc.*

      American Society for Bone and
      Mineral Research2

      Basilea Pharmaceutica International Ltd.4

      BioTeam *

      CereSpir, Inc.

      Chiesi Farmaceutici S.p.A.5

      EUROIMMUN

      Foundation for Advanced Education
      in the Sciences2

      Matthew M. Frank and Shahin Jansepar

      Friends of Cancer Research5

      Estate of Jack Gramlich4

      Steve and Sherry Mayer2

      Melinta Therapeutics

      Mitsubishi Tanabe Pharma Corporation2

      Drs. Martin J. and Ann Murphy9
      in honor of Dr. and Mrs. Charles A. Sanders

      Myriad RBM2

      Neurotrack Technologies

      Bob and Sally Newcomb4

      OfficeMax Incorporated2

      Beatrice & Reymont Paul Foundation

      James and Lisa Reinish
      in memory of Shelby Brooke Reinish

      Dr. and Mrs. Charles A. Sanders18

      Jane M. Sayer, Ph.D.13

      Dr. Ellen V. and Mr. Gerald R. Sigal12

      Solomon H. and Elaine B. Snyder

      Tetraphase Pharmaceuticals

      University of Sciences, Techniques,
      and Technology of Bamako*

      $5,000–$9,999

      Anonymous

      Catholic Health Initiatives

      Centre for Proteomic & Genomic Research2

      Dairy Management Inc.4

      Miles Gilburne and Nina Zolt5

      Carol-Ann Harris2

      James W. Jones
      in memory of Brenda Jones

      Kelly and Adam Leight2

      Stephen and Maria Maebius
      in honor of Erica Maebius

      Metabolon, Inc.2

      Profilo Holdings

      Radiological Society of North America6

      Raycom Media., Inc.
      in memory of Edward Rancic

      Robert E. Roberts, Ph.D.6

      John and Trina Rogers
      in memory of Brenda Jones

      Matthew Scher and Barbara Lazio2
      in memory of Barbara Lazio and Carol Scher

      SOHO Publishing Company3

      Nina K. Solarz5

      Drs. Elias A. and Nadia Zerhouni2

      [_/su_spoiler]
      $500–$4,999

      $2,500–$4,999

      Ronald and Barbara Berke5
      in memory of Jennifer Berke

      The Honorable and Mrs.
      William McCormick Blair, Jr.

      Elsevier Life Science Team7
      in honor of the Gallins

      Joseph M. Feczko, M.D. and
      Leighton K. Gleicher7

      Fisher Foundation

      Drs. Ernesto I. and Maria C. Freire3

      Paul J. Gattini3

      Chris and Laura Hazzard6
      in memory of Richard Curtin

      Conrad N. Hilton Foundation

      U.S. Senator Amy Klobuchar2

      Dr. Mehdi Nafissi and Dr. Ann F. Welton7

      Dr. and Mrs. Garry A. Neil3

      Donna Nichols 5
      in memory of Jay Nichols

      Matt and Robyn Nichols Painter4
      in memory of Jay Nichols

      Lenore R. Salzman17

      Simon Property Group5

      SunTrust Banks, Inc.4

      Samuel O. Thier, M.D. and Paula Thier9

      Ullmann Family Foundation6

      Steve and Chris Wilsey6

      $1,000–$2,499

      Anonymous (6)

      AcademyHealth

      Affymetrix Inc.

      Ronald A. and June L. Ahrens3
      in memory of Xavier Martin

      Dr. Nadarajah Balasubramanian
      in honor of Dr. Heiss

      Raghu Bellary2

      Joe Bergera and Alice S. Cho2

      The Honorable and Mrs. Wayne Berman

      Dr. Kathy and Mr. Zachary T. Bloomgarden6

      Ambassador and Mrs. Dwight L. Bush, Sr.

      Mr. Charles Cerf and Dr. Cynthia E. Dunbar4

      Timothy Coyle
      in honor of the Coyle Family

      David Crammer

      Daniel Cunningham and Mary Hennessey

      Stewart Daniels, M.D.6

      Rob and Betsey Drucker3

      Marianne E. Durkin2

      Jack A. Elias, M.D.2

      Faegre Baker Daniels LLP

      Fannie Mae Foundation

      James M. Felser, M.D.5

      Nicholas M. and Jacqueline E. Ferriter

      Seth P. Forster

      Morgan A. Fritzlen
      in honor of Dr. Neal Young

      Thomas and Jerrice Fritzlen
      in honor of Dr. Neal Young

      James and Karen Gavic5

      Stanley and Eve Geller9
      in memory of Norman Salzman

      Peggy J. Gerlacher17

      Eli Glatstein11

      The Goldman Sachs Group, Inc.

      Dr. and Mrs. Sam D. Graham4

      [x] Superscript indicates number of years of consecutive giving.
      * Indicates Gifts in Kind.

      Margaret Grieve 2
      in honor of Nina Solarz’s birthday

      Gary and Lynn Grossman4
      in honor of Stephen J. Solarz’s birthday

      Judy Harris

      Eric and Susan Hatch
      in honor of Dr. W. Marston Linehan

      Harley Anderson Haynes, M.D.5

      Paul Herrling, Ph.D.

      Arthur and Susan Horowitz3

      Pansy M. Howard

      Jonathan Howard2

      IQ Solutions5

      Jimmy Beans Wool3

      Daniel Kastner, M.D., Ph.D.

      Bernard H. and Georgina E. Kaufman5

      Paul Lam

      Sherry Lansing and William Friedkin2

      Howard H. and Jacqueline K. Levine4
      in memory of Stephen J. Solarz

      Jonathan D. Levine4
      in memory of Stephen J. Solarz

      Jean Linton12

      Edison T. Liu, M.D., Ph.D. 2

      James and Marie Malaro

      The Honorable and Mrs. Frederic V. Malek

      Merrill Lynch & Co., Inc.

      Susanne N. O’Neill

      Matthew W. O’Neill and Erica Joyce Lam8

      Amy L. Parker

      Steven and Jann Paul4

      Joseph G. Perpich, M.D., J.D.
      and Cathy J. Sulzberger
      in honor of John Porter

      Amy and John Porter15

      Sunny Raspet2

      The Essence of Red Committee4

      Ridley, Inc.

      Charles P. Rogers Beds2

      Gregory and Sherry Roper

      Mark Rosen

      Robert and Marjorie Rosenberg4

      Shire Pharmaceuticals, Inc.

      Albert H. and Lillian Small

      Richard I. and Anastasia Smith2

      Russell W. Steenberg and Patricia Colbert2

      The Drs. Tremoulet6

      Marica and Jan Vilcek3

      Gail G. Weinmann, M.D.3

      Michael and Lisa Nichols Whitten2
      in memory of Jay Nichols

      Stewart K. Wilson3
      in memory of Blaise Ribet

      World Bank
      in memory of Ewen Raballand

      $500–$999

      Anonymous (2)

      Jeffrey and Ann Anderson

      Drs. Bryan and Donna Arling10

      Ann Ashby and Ron Kopicki4

      Bruce J. Averbrook5

      Dan Balliet and Jan Carlson6

      Kathryn H. Bedell

      Paula L. and William C. Bradley

      Jeffrey Broome

      The Honorable and Mrs. Zbigniew Brzezinski

      Jan Chipman

      Arthur Ciarkowski
      in honor of Lois Cosner

      Scot Jason Cohen Foundation Inc.

      The Consortium of Multiple
      Sclerosis Centers Inc.

      Dorothy Davies
      in memory of Margaret Elkind Van Gelder

      Jerry and Kathy Devore

      Johanna Caramel Egan

      Martin Friedlander, M.D. and
      Sheila F. Friedlander, M.D.

      Ken and Yvette Guidry8

      Linford M. Hallman2

      Barry and Sandy Harris

      Kay A. Hart4

      Alison Harvey

      Amy W. Hawthorne2

      Eva C. Holtz5

      Robert Hughes Family Foundation

      Laurel Jacobson5
      in memory of Stephen Jacobson

      Vernon and Ann Jordan

      Michael M. Kaback, M.D.

      Benjamin Kasoff

      Charles E. Kaufman Medical Fund3

      Ronald L. Krall, M.D.3

      Jeremy Krasner3

      Georges Laine
      in memory of Ewen Raballand

      Dr. and Mrs. Ronald W. Lamont-Havers5

      Peter Lane2

      Susan Luse
      in memory of Gregory Fager

      M & J Management Co., LLC

      John Madden2

      John and Stacy Martin2

      Robert and Margaret McNamara Foundation2
      in memory of Stephen J. Solarz

      Molecular Partners AG
      in honor of Donald Bottaro

      Jorge Morazzani

      Dr. Gilbert S. Omenn and
      Mrs. Martha Darling4

      PharmAthene, Inc.

      Lola Reinsch

      Dr. and Mrs. Johng S. Rhim3

      Eric I. Richman

      Richard and Jean Robbins

      James and Lora Rodenberg5
      in memory of Dennis Rodenberg

      Tali Rombro
      in memory of Jane Lochary

      Stanley O. Roth

      Barbara Santos
      in memory of Carlos Santos

      Howard K. Schachman10
      in memory of Ethel Schachman

      Laura Sergent
      in memory of Kathleen C. Sergent

      Charles H & Beverly E Shaw Foundation
      in memory of Margaret Elkind Van Gelder

      Danny Shively2

      Cyrena Simons

      Richard and Luan Smith
      in memory of Gregory Fager

      Mr. Suresh Subramani and
      Ms. Feroza Ardeshir

      Jon and Kristin Vaver7

      Dr. and Mrs. Roy Weiner

      David Wholley and Mary M. O’Crowley3

      Nicole Wolanski

      Lucas Yun-Nikolac

      [_/su_spoiler]
      $250–$499

      $250–$499

      Anonymous (6)

      Macia Anderson
      in memory of Shelby Reinish

      Jill H. Barr6
      in memory of John Barr

      Brenda L. Bass, Ph.D.
      in memory of Ernest Bass

      Joan Beck4

      Edwin D. Becker

      Thomas Brunner
      in honor of Paul Sieving

      Tino and Dawn Calabia

      Daniel Carucci, M.D., M.Sc., Ph.D.5

      Michael and Melissa Cather

      Michael Cohen

      Edward G. Conture, Ph.D.2

      Craig Corbitt and Nancy Stoltz5

      Martin J. Corso, M.D.2

      Creech Family and Costello Elementary

      Arlene and Richard Crowell8

      Vickram and Sarah Cuttaree
      in memory of Ewen Raballand

      Denise Interchangeable Knitting Needles3

      Garth M. Eddy

      Drs. Howard J. Eisen and Judith E. Wolf

      Shauna Ensrud

      F5 Networks

      Melinda Fager

      Lisa Foronda
      in memory of Judy Foronda

      Arlyn Garcia-Perez

      Jason and Gloria Garver8

      Drs. David Golan and Laura Green4
      in honor of Deborah Merke

      Reina Gonzalez
      in memory of Carlos Santos

      Joseph Grossman3

      [x] Superscript indicates number of years of consecutive giving.
      * Indicates Gifts in Kind.

      Parker and Kiki Gundersen

      Dr. Max I. Hamburger

      Joyce Harp, M.D.

      James and Mary Louise Hayden

      Robert Heady2

      Eric Hirschhorn and Leah Worthham4

      1. & A. Holtzman Foundation

      Carol Horn
      in memory of Gregory Fager

      I Back Jack Foundation Inc.

      Stephanie L. James, Ph.D.4

      Richard Jonas and Katherine Vernot-Jonas7

      Dr. and Mrs. Michael Kaliner2

      John Kennedy5

      Dr. and Mrs. David A. Kessler
      in memory of Gregory Fager

      Edward Koo

      Sandy Kotiah
      in memory of Jessica Payne

      Beth Kramer
      in memory of Ewen Raballand

      Melissa Kuskin5
      in memory of Bennett Bruce Camhi

      Dr. and Mrs. Theodore S. Lawrence

      Thomas and Nancy Lusk

      James Mahoney

      David Marsden
      in honor of Abby Holtz & Lorant Szasz-Toth

      Anne Alexander Marshall, Ph.D.
      and Davis Marshall10

      Cathleen Martin2

      Dr. and Mrs. Henry Masur

      Pedro Morazzani

      Sara Morningstar
      in memory of Ewen Raballand

      Eileen Murray
      in memory of Ewen Raballand

      Diep Nguyen-van Houtte
      in memory of Ewen Raballand

      Ingrid Ostergren

      Alice Pau

      Charles Payne
      in memory of Laurie Payne

      Plymouth Yarn Company3

      Roger Reading
      in memory of Lisa Sapak

      Lawrence Rogow
      in memory of Gregory Fager

      Jeffrey Rosen

      Walter G. Rostykus and
      Catherine Elliott-Rostykus

      Dr. Michael Ryan and Dr. Linda Ryan2

      Nikhil Sadarangan

      Michael Samelson

      Cecelia Spitznas

      Rainer F. Storb, M.D.

      Anthony Tassone3

      Ryan Temming2

      Arlene Urquhart4

      Eric Van Gelder
      in memory of Margaret Elkind Van Gelder

      Richard and Tracy Nichols Waggoner2
      in memory of Jay Nichols

      Michael and Marianne Walter

      Paula J. Warrick, Ph.D.3

      Robert C. Watson and Debra D. Petersen4

      Sara Lou Whildin2

      Ingrid Wiley6

      Peggy Williams, Jame Regam Considine,
      and Sarah Underhill
      in memory of Gregory Fager

      John H. Wilson6

      Howard and Julie Wolf-Rodda8

      Carol Shaw Woodard
      in memory of Margaret Elkind Van Gelder

      Joyce A. Yarington11
      in memory of Jan Weymouth

      Joel Yesley7

      [_/su_spoiler]
      GIVING SOCIETIES

      LEGACY SOCIETY

      The Legacy Society recognizes individuals who have informed us that they have named the Foundation for the NIH as a beneficiary in their will or estate plan. These legacy gifts can support a specific NIH program, area of research or other identified need, or they may provide unrestricted support to the Foundation. We thank the following individuals who have named the Foundation as a beneficiary.

      Anonymous (4)

      Judy Belous

      The Honorable and Mrs.
      William McCormick Blair, Jr.

      Estate of William R. Boyle

      Paula L. Bradley

      Buffy and William Cafritz

      Michael Davis

      Estate of Sallie Rosen Kaplan

      Marjorie D. Fuller

      Estate of Charles Harris

      Patricia S. and Ken Kohlen

      Drs. Zell and Emily Kravinsky

      Patricia Nowosacki

      Estate of Jennifer R. Price

      Robert E. Roberts, Ph.D.

      Estate of Frances H. Saupe

      Jane M. Sayer, Ph.D.

      Gail G. Thompson

      Rita Visconte

      Dr. and Mrs. Robert F. Wagner

      Susan M. Wall, M.D.

      HONORARIUM GIFTS

      You can honor a friend or family member for an important occasion with a gift to the Foundation for the NIH. It is a wonderful way to send good wishes for a birthday or anniversary, thanks to a friend or doctor, or congratulations for retirement, a job well done or graduation. Please include the name and address of the individual being honored so that acknowledgement of your donation can be sent. In 2014, the Foundation received gifts in honor of the following individuals.

      Robert Albers

      Jeff Balow

      Jill Balow

      Mary Jo Balow

      Richard Balow

      James Bante

      Susan Bante

      Brielle Barber

      Elaine Benedetto

      Donald Bottaro

      Katy Burkert

      Lois Cosner

      The Coyle Family

      Kay Cowan

      Kelsey Doucette

      Garth M. Eddy

      Christina Farias

      Antonio T. Fojo

      Maria C. Freire

      Elaine K. Gallin

      John I. Gallin

      Ari Goldman

      Samir Hajj

      Kathleen Haley

      Constance Hanson

      Nancy Haywood

      Christopher Heery

      John D. Heiss

      Abby Holtz

      Arthur G. Horowitz

      Nancy L. Hughes

      Andrew Leonhardt

      W Marston Linehan

      Erica Maebius

      Deborah Merke

      Erica S. Morrison

      William Murphy

      Hyman Muss

      Brian R. O'Neill

      Israel O. Oyelakin

      Christie Pedder

      Simon Pedder

      Katherine G. Peterson

      John E. Porter

      Brayden M. Preble

      Laura Ritchie

      Skylar Ritchie

      Kristen S. Roach

      Brad Roden

      Saul Roseman

      Mark Rosen

      Charles A. Sanders

      Alan N. Schechter

      Christine Sidelko Titley

      Paul A. Sieving

      Nick Silano

      Nina K. Solarz

      Kimberly Stemple

      Ashleigh Stoddart

      Debbie Sullivan

      Kevin Sullivan

      Lorant Szasz-Toth

      Betsy Templeton

      Chrisa Thomas

      Adam Wolpaw

      Neal S. Young

      Stuart H. Yuspa

      MEMORIAL GIFTS

      Contributions are given to the Foundation for the NIH at the request of family members in memory of loved ones. These generous contributions enhance our ability to support the NIH in its mission to improve health, by forming and facilitating public-private partnerships for biomedical research, education and training. We extend our sympathies to the family and friends of those memorialized below.

      Bernard W. Abrams

      Janice Alfano

      Ruth Auslander

      Eileen L. Baldassari

      Mary Bante

      John L. Barr

      Keith Bartosh

      Ernest G. Bass

      George Beck

      Karol Bell

      Jenny Berke

      Adam J. Berry

      Francis Beswick

      Lynne A. Buening

      Todd Burdick

      Kathleen Buter

      Bennett Bruce Camhi

      Veronica S. Cassell

      Pavlos Charalambous

      Colin Chignell

      Scott A. Chizzo

      Helen Clark

      Laura Cliffe

      James Cribbs

      Richard Curtin

      Elizabeth Dooley

      Iva Dostanic

      Janis Evans

      Gregory B. Fager

      David M. Feit

      Joanne M. Ficks

      Leslie Fitzgerald

      Judy Foronda

      Jean R. Fuller

      Patricia Anne Gelak

      John D. Gerlacher

      William Glaubiger

      Hugo Grenti

      Christopher Hamilton

      Kelly M. Harty

      Mary C. Hennick

      Lloyd A. Hershey

      Gary Hogden

      James V. Hudson

      Agneta Hughes

      Stephen W. Jacobson

      Harold Jellinek

      Brenda S. Jones

      Gerald E. Kerns

      Robert Kleber

      Arthur Koch

      Wesley J. LaPorte

      Gene Lasecki

      Richard Lauderbaugh

      Barbara L. Lazio

      Erik J. Lemoine

      Lawrence Linn

      Stephen Liptak

      Jane Lochary

      Nicoletta M. Lombard Cerio

      Ellen Lundevall

      Catherine Malavendra

      Xavier Martin

      Patrick J. Marx

      Michael J. McKinnon

      John N. Miller

      Frank Myers

      Hannah Naylor

      Stan C. Nebinski

      Jay Nichols

      Dean R. O'Neill

      Chin Ki Paik

      Laurie Payne

      Susan Pilch

      Lindsey Powell Rensch

      Jennifer R. Price

      Ewen Raballand

      Joan E. Radula

      Edward Rancic

      Shirley Ray

      Raymond C. Read

      Shelby B. Reinish

      Blaise Ribet

      Mary Richards

      Douglas H. Riedy

      Mary Lee Rodda

      Dennis Rodenberg

      Gladys Rodriguez

      Linda Rozzelle

      Hyacinth Rubin

      Kathleen Rudis

      Catherine Ryan-Beuttenmuller

      Norman P. Salzman

      Carlos Santos

      Lisa Sapak

      Ethel L. Schachman

      Arthur G. Schatzkin

      Carol Scher

      Katherine Schumacher

      Kathleen C. Sergent

      Helen Shen

      Melissa Sheperd

      Charles Slonim

      Stephen J. Solarz

      Haim Solomon

      Mikhail Spitkovsky

      Emily Stevens

      Nathan W. Synan

      Oberon Christopher Thoma

      Paul Toole

      Margaret Elkind Van Gelder

      Lisa J. Wagner

      Janice Weymouth

      Margaret G. White

      Nathan Williams

      Roseana Woodberry

      William J. Yates

      [_/su_spoiler]
      Funds & Endowments

      We are grateful to the many individuals and organizations that have established funds or endowments at the FNIH to pay tribute to people and causes that matter to them. Such gifts provide essential ongoing support for research and education, as well as events in biomedicine at the NIH. Endowment gifts at all levels help to advance the pace of discovery and generate innovations that improve lives.

      NAMED FUNDS

      Named funds are created to support specific areas of research or fellowships, lectures or awards at the NIH.

      John I. and Elaine K. Gallin Fund
      This fund provides support for the Edmond J. Safra Family Lodge and to support patient and clinical research needs of the intramural research program at the National Institutes of Health.

      Gramlich Melanoma Research Fund
      This fund supports melanoma research at the NIH through an annual gift provided by the Jack Gramlich Foundation.

      The Dr. Franklin A. Neva Memorial Fund
      The Neva Fund was established by the family of Dr. Frank Neva, a former director of the NIAID Laboratory of Parasitic Diseases (LPD) at the NIH, to honor his memory and further his legacy. Dr. Neva was keenly interested in teaching and learning through case-based discussions and he transformed the LPD into a pre-eminent center for basic and clinical parasitology research and training.

      Richard and Susan Roth Fellowship


      The Richard and Susan Roth Fellowship supports research in the lab of Dr. Jeffrey Cohen of National Institute of Allergy and Infectious Diseases (NIAID) to accelerate efforts to find new drugs to treat Chronic Active Epstein Barr Virus (CAEBV) and Chronic Active Epstein Barr Virus-Hydroa Vacciniforme (HV) as well as find and understand genetic causes of the diseases that can lead to new treatments.

      Sayer Vision Research Fund
      This fund supports the annual Sayer Lecture delivered by an investigator in the area of vision research, as well as the Sayer Vision Research Award, given to a promising independent investigator in the early stage of his or her research career in the Division of Intramural Research at the National Eye Institute. The fund was established by NIH research scientist Jane Sayer, in honor of her family and in memory of her parents, Winthrop and Laura Sayer.

      Swanson Family Fellowship
      The Swanson Family Fellowship supports research in TTF-1 mutation-causing benign chorea in the laboratory of infectious diseases under the direction of Steven M. Holland, M.D., Chief of the Laboratory of Clinical Infectious Diseases, NIAID.

      [_/su_spoiler]
      MEMORIAL FUNDS

      Memorial funds create a living legacy. In many cases a family member may request that friends and relatives make donations—rather than send flowers—to support a chosen cause in memory of a loved one. Families may wish to go one step further and establish a fund that embodies a loved one’s passion and spirit by making a significant investment in the Foundation.

      Dr. John L. Barr Memorial Fund
      This fund helps to support the Intramural Research Training Award Fellowship Program at the NIH Clinical Center’s Pain and Palliative Care Service. The goal of the fellowship is to conduct research on pain and palliative care and to encourage young investigators to become more familiar with the importance of this field of study.

      Adam J. Berry Memorial Fund
      This fund was established by Michael and Sue Berry in memory of their beloved son, Adam. Adam came from Australia to work as a research scientist at the National Cancer Institute (NCI). The fund commemorates his life and his enthusiasm for work by making it possible for promising young Australian scientists to travel to the United States and work at the NIH.

      Edna Williams Curl and Myron R. Curl Fundfor Multiple Sclerosis Research
      Established in 2007, this fund supports multiple sclerosis research at NIH.

      John Laws Decker Memorial Fund
      A former director of the NIH Clinical Center, Dr. John Laws Decker strived during his lifetime to accelerate important scientific research by linking research communications around the world. His dedication led the NIH to establish an annual lecture in his name. This fund, established by the Decker family, supports an event for the lecturer each year.

      Tracy’s Toy Box
      Established by the family in memory of Tracy Nadel, this fund purchases toys and activities for children staying at the Edmond J. Safra Family Lodge. These items help make their time at the Lodge more comfortable and pleasant.

      Dean R. O’Neill Renal Cell Cancer
      Research Fund
      This fund supports a fellowship in the laboratory of tumor immunology headed by Richard Childs, M.D., at NHLBI. The postdoctoral cancer investigator funded by the program conducts research on the treatment of renal cell (or kidney) cancer. Family and friends of the late Dean O’Neill established the fund; more information can be found at www.renalcellcancer.org. The family also organizes the annual Boo! Run for Life 10K race and two-mile walk to support the fund. Information about the Boo! Run, held annually in October, can be found at www.boorunforlife.com.

      Dr. Edward T. Rancic Memorial Fund
      This fund supports a post-doctoral fellowship that focuses on renal cell cancer research in the laboratory of tumor immunology headed by Richard Childs, M.D., at NHLBI. The fellowship was established in memory of Dr. Edward Rancic by his family.

      Dr. Anita Roberts Memorial Fund
      Widely recognized as an outstanding mentor, encouraging and inspiring young scientists, Dr. Roberts was one of the first female laboratory chiefs at the NIH and ranked in the top 50 most-cited biological scientists in the world. Her family and laboratory colleagues established the fund to allow graduate students and post-doctoral fellows to present their work at a national meeting, typically the TGF-beta Keystone Symposium. These scholarships are a fitting tribute to Dr. Roberts’ passion for encouraging the career development of young scientists.

      Robert Whitney Newcomb Memorial Fund
      This fund was established by the family to remember Dr. Newcomb, who began his scientific career at the NIH as a high school summer intern in a laboratory at the NCI. The fund endows an annual lecture by a recognized expert in neuroscience, selected by the National Institute of Neurological Disorders and Stroke (NINDS). Honoring Dr. Newcomb’s own experience, it also provides for internships for high school students and fellowships at NINDS.

      Stephen J. Solarz Memorial Fund
      Nina Solarz established this fund in memory of her husband, former Congressman Steve Solarz, to support the research of Dr. David Schrump at NCI. Dr. Schrump’s pioneering research in the field of thoracic oncology led to the treatments that allowed Mr. Solarz to live years beyond what otherwise would have been possible. Before he died, Nina and her family dedicated themselves to supporting Dr. Schrump’s research so that other patients might benefit by even better treatments.

      Stephen E. Straus Fund
      Established by Bernard and Barbro Osher in 2006, this fund honors the founding director of the NIH’s National Center for Complementary and Alternative Medicine (NCCAM), the late Dr. Stephen E. Straus. It supports the Stephen E. Straus Distinguished Lecture in the Science of Complementary and Alternative Medicine, an annual lecture that brings leading figures in science and medicine to the NIH to speak about their perspective on the field. Open to the public, the lecture is videocast and archived on the NCCAM website.

      [_/su_spoiler]
      ENDOWMENTS

      Through these endowment gifts, donors ensure perpetual support for a variety of research and educational initiatives at FNIH. The annual investment income generated by an endowment fund supports program expenses, while the principal remains intact to ensure future funding.

      Sallie Rosen Kaplan Fund for
      Women Scientists in Cancer Research
      The Kaplan Fund, established in 2000, provides support for the retention and mentoring of outstanding female cancer research scientists in the field. The program is managed by the National Cancer Institute.

      Norman P. Salzman Memorial Fund
      Dr. Salzman’s family, colleagues and friends remember the legacy of this noted pioneer in molecular biology through contributions to this fund, which supports the annual Norman P. Salzman Memorial Award and Symposium in Virology. The half-day symposium addresses key topics in virology and immunology and presents an award to a young researcher, in recognition of Dr. Salzman’s mentorship of so many younger scientists.

      Endowments in support of the
      Edmond J. Safra Family Lodge
      Through endowment gifts, donors ensure perpetual support to the Edmond J. Safra Family Lodge for its operations and for the continued comfort of its guests.

      GlaxoSmithKline Endowment
      The GlaxoSmithKline Endowment supports programs and activities for families, including services that help residents stay in touch with employers and loved ones.

      CarMollNat Muscular Dystrophy Endowment
      The CarMollNat Muscular Dystrophy Endowment was established by Carol-Ann Harris in memory of her parents, Molly and Nathan Harris, and her brother, Merton Harris. The goals of the CarMollNat Endowment are to support research, science and wider knowledge, specifically for the many afflicted with Muscular Dystrophy (MD) and neuromuscular and neurogenetic diseases.The Endowment supports research at the Neurogenetics Branch of the National Institute of Neurological Disease and Stroke (NINDS).

      Harry and Jeanette Weinberg Endowment
      The Weinberg Endowment supports Edmond J. Safra Family Lodge operations and maintenance—ensuring that guests are provided a comfortable home away from home for years to come.

      Additional Funds:
      Jerry D. Jennings Memorial Fund

      NCI Neuro Oncology Branch Fund

      Pain and Palliative Care Program, Roxane Institute Fund

      Research in Congenital Adrenal Hyperplasia

      [_/su_spoiler]

      Board of Directors & Our Staff

      Open post
      Board of Directors

      Charles A. Sanders, M.D. (Chairman)
      Retired Chairman and CEO, Glaxo, Inc.

      Mrs. William McCormick Blair, Jr. (Secretary)
      Director Emeritus, Albert and Mary Lasker Foundation

      Kathy Bloomgarden, Ph.D.
      Chief Executive Officer, Ruder Finn, Inc.

      Mrs. William (Buffy) N. Cafritz
      Trustee, The John F. Kennedy Center for
      the Performing Arts

      Mr. James H. Donovan
      Partner, Goldman Sachs & Company;
      Adjunct Professor, University of Virginia

      Joseph Feczko, M.D.
      Retired Senior Vice President & Chief
      Medical Officer, Pfizer Inc.

      Maria C. Freire, Ph.D.
      President and Executive Director,
      Foundation for the National Institutes of Health

      Mr. Miles Gilburne
      Managing Member, ZG Ventures, LLC

      Paul L. Herrling, Ph.D.
      Chairman, Novartis Institute for Tropical Disease

      Ronald L. Krall, M.D.
      Former Senior Vice-President and
      Chief Medical Officer, GlaxoSmithKline

      Ms. Sherry Lansing
      Chief Executive Officer,
      The Sherry Lansing Foundation

      Freda C. Lewis-Hall, M.D.
      Chief Medical Officer, Senior Vice President,
      Pfizer Inc.

      Edison T. Liu, M.D., Ph.D.
      President and Chief Executive Officer,
      The Jackson Laboratory

      Ms. Ann Lurie
      Lurie Holdings, Inc., Ann & Robert H. Lurie Foundation

      Mr. Joel S. Marcus
      Chairman, CEO, President and Founder,
      Alexandria Real Estate Equities, Inc.

      Mr. Steven C. Mayer (Treasurer)
      Retired EVP & CFO, Human Genome Sciences;
      Retired Founder & CEO, CoGenesys, Inc.

      Paul M. Montrone, Ph.D.
      Chairman, Perspecta Trust

      Martin J. Murphy, Jr., Ph.D.
      Chairman & Chief Executive Officer,
      AlphaMed Consulting, Inc.

      Garry A. Neil, M.D.
      Global Head R&D, Medgenics, Inc.

      Steven M. Paul, M.D.
      President & CEO, Voyager Therapeutics, Inc.

      The Honorable John Edward Porter
      (Vice Chairman for Policy)
      Hogan Lovells US, LLP

      Mrs. Jillian Sackler, D.B.E.
      President and CEO, AMS Foundation for the Arts,
      Sciences and Humanities

      Mrs. Lily Safra
      Chairwoman, The Edmond J. Safra
      Philanthropic Foundation

      Ellen V. Sigal, Ph.D.
      Chairperson, Friends of Cancer Research

      Solomon H. Snyder, M. D.
      (Vice Chairman for Science)
      Distinguished Service Professor of Neuroscience,
      Johns Hopkins University School of Medicine

      Ms. Nina K. Solarz
      Former Executive Director of Peace Links
      and the Fund for Peace

      Samuel O. Thier, M.D.
      Professor of Medicine and Health Care Policy,
      Emeritus, Harvard Medical School,
      Massachusetts General Hospital

      Anne Wojcicki
      Chief Executive Officer and Co-Founder, 23andMe

      HONORARY DIRECTIONS

      Luther W. Brady, M.D.
      Distinguished University Professor,
      Drexel University College of Medicine

      Patrick C. Walsh, M.D.
      University Distinguished Service Professor of
      Urology, Johns Hopkins Medical Institutions

      DIRECTOR EMERITUS

      Paul Berg, Ph.D.
      Cahill Professor in Biochemistry (Emeritus),
      Stanford University School of Medicine

      EX-OFFICIO

      Francis S. Collins, M.D., Ph.D.
      Director, National Institutes of Health

      Margaret A. Hamburg, M.D.
      Commissioner, Food and Drug Administration

      Our Staff

      PRESIDENT’S OFFICE

      Maria C. Freire, Ph.D.
      President and Executive Director

      Ann Ashby, M.B.A.
      Deputy Executive Director

      Andrea Baruchin, Ph.D.
      Senior Advisor to the President

      Erika Tarver
      Senior Project Manager

      Felicia Gray
      Executive Assistant

      Elizabeth S. Johns
      Executive Assistant

      Kathy Peterson
      Operations Officer

      FINANCE

      Julie, Tune, C.P.A., C.F.E.
      Chief Financial Officer

      Eva Coyne, C.P.A.
      Controller

      Cathy Martin, C.P.A.
      Senior Accountant

      Noemi B. Rodriguez
      Staff Accountant

      Peggy J. Gerlacher
      Operations Associate

      EVENTS AND MARKETING

      Jolie Mak
      Events Manager

      Jasmin Miles, C.M.P.
      Senior Events Coordinator

      Andrea Hickman
      Events Coordinator

      Janelle Lewis
      Events Coordinator

      Sarah Kay
      Events Assistant

      DEVELOPMENT

      Julie Wolf-Rodda, M.A.
      Director of Development

      Renée Bullion, M.P.A.
      Development Officer

      Meredith Donnelly
      Development Officer

      Emily Acland
      Development Officer

      Jillian Bante
      Development Assistant

      William Tolentino
      Development Systems Administrator

      ADVANCEMENT

      Melissa Cather, C.F.R.E.
      Director of Advancement

      Rob Drucker, J.D.
      Partnership Development Officer

      Laren Friedman, M.F.A.
      Writer/Researcher

      SCIENCE ADMINISTRATION

      Stephanie James, Ph.D.
      Director of Science

      Michael Gottlieb, Ph.D.
      Deputy Director of Science

      Dennis Lang, Ph.D.
      Senior Program Coordinator, MAL-ED
      (contractor)

      Karen Tountas, Ph.D.
      Scientific Program Manager, MAL-ED

      Gail Levine, M.A., C.R.C.C.
      Scientific Program Manager, CTC-VIMC

      Susan Powell, M.T.S.
      Senior Grants Manager

      Susan Wiener, M.A.
      Senior Project Manager, GCGH

      Anna Sambor, M.S.
      Program Manager

      Tiffany Francis
      Grants and Administrative Assistant

      RESEARCH PARTNERSHIPS

      David Wholley, M.Phil.
      Director of Research Partnerships

      Maria Vassileva, Ph.D.
      Senior Scientific Program Manager,
      Metabolic Disorders

      Sonia Pearson-White, Ph.D.
      Scientific Program Manager, Cancer

      Steve Hoffmann, M.S.
      Scientific Program Manager, Inflammation
      and Immunity

      Rosa Canet-Aviles, Ph.D.
      Scientific Program Manager, Neuroscience

      Paula Eason, Ph.D.
      Scientific Program Manager, Cancer

      Dorothy Jones-Davis, Ph.D.
      Scientific Project Manager

      Sanya Whitaker, Ph.D., P.M.P.
      Scientific Project Manager

      Jessica Ratay, M.S.
      Clinical Project Manager

      Cheryl Melencio
      Executive Assistant

      Jessica Jones
      Administrative Assistant

      COMMUNICATIONS

      Richard Folkers
      Director of Communications

      Kai Yee
      Digital Administrator

      INTERNS

      Emma Bradford

      Amber Langway

      Anisa Sanghrajka